Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Accumulated Depreciation (2022 - 2025)

Stoke Therapeutics has reported Accumulated Depreciation over the past 4 years, most recently at $10.1 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation at $10.1 million for Q4 2025, up 14.67% from a year ago — trailing twelve months through Dec 2025 was $10.1 million (up 14.67% YoY), and the annual figure for FY2025 was $10.1 million, up 14.67%.
  • Accumulated Depreciation for Q4 2025 was $10.1 million at Stoke Therapeutics, up from $8.8 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for STOK hit a ceiling of $10.1 million in Q4 2025 and a floor of $4.2 million in Q4 2022.
  • Median Accumulated Depreciation over the past 4 years was $7.8 million (2023), compared with a mean of $7.5 million.
  • Biggest five-year swings in Accumulated Depreciation: surged 58.57% in 2023 and later grew 14.67% in 2025.
  • Stoke Therapeutics' Accumulated Depreciation stood at $4.2 million in 2022, then surged by 58.57% to $6.7 million in 2023, then soared by 32.63% to $8.8 million in 2024, then grew by 14.67% to $10.1 million in 2025.
  • The last three reported values for Accumulated Depreciation were $10.1 million (Q4 2025), $8.8 million (Q4 2024), and $6.7 million (Q4 2023) per Business Quant data.